ABSTRACT
The spread and consequences of the coronavirus disease 2019 (COVID19) pandemic are currently one of the most pressing public health challenges in the world. Despite the fact that experience accumulates in the treatment and monitoring of COVID19 patients, certain aspects are still a clinical dilemma. In particular, this regarded the use of nonsteroidal antiinflammatory drugs (NSAIDs) during the pandemic, both as a symptomatic treatment of infection, and in patients with comorbidities requiring NSAID. A series of studies did not establish evidence of the risk of infection and complications from NSAID therapy in COVID19. At the same time, the practitioner should take into account the risk of specific NSAIDassociated complications, which also remain relevant during the COVID19 pandemic. This resolution focuses on the evolution of ideas about NSAID use and safety in COVID19, and also emphasizes the particular relevance of their use for a number of clinical situations. © 2022 Vserossiiskoe Obshchestvo Kardiologov. All rights reserved.
ABSTRACT
Cognitive impairment (CI) can be neurological symptoms or complications of coronavirus disease 2019 (COVID-19). Among the pathogenetic mechanisms, the neurotropicity of the SARS-CoV-2 virus, endothelial dysfunction, coagulopathy, thrombus formation, systemic inflammatory reaction, the consequences of mechanical ventilation and drug sedation are considered. Treatment strategies for COVID-19 patients with CI have not yet been developed. The following tactics of patient management is advisable: prevention of re-infection, assessment and correction of the emotional state, treatment of cardiovascular diseases. The possibilities of vinpocetine in the treatment of CI after COVID-19 are discussed. © 2021 Ima-Press Publishing House. All rights reserved.